Alopecia areata (AA) is autoimmune: the immune system attacks hair follicles, causing round bald patches or, in severe cases, total scalp (alopecia totalis) or whole-body (universalis) loss. It is not androgenetic pattern loss, so minoxidil and finasteride are not the answer. The breakthrough is a class of oral drugs — JAK inhibitors — that calm the immune attack: baricitinib (Olumiant, FDA-approved for AA in 2022), ritlecitinib (Litfulo, 2023, from age 12), and deuruxolitinib (Leqselvi, approved 2024 and launched in 2025). In severe AA, a meaningful share of patients regrow substantial hair over 6-12 months, but the benefit can fade if the drug stops, and these are immune-modulating medicines with boxed warnings (serious infections, blood clots, some cancers) that need a dermatologist's screening and monitoring. They are also costly and not always covered. If you have sudden round patches, short broken 'exclamation-mark' hairs, or rapid widespread loss, see a dermatologist — AA is treatable, and the JAK era has genuinely changed the outlook.
Try the free self-check →Sources: AGA review (CCID) ↗
FAQ
Is alopecia areata the same as male or female pattern baldness?
No. Alopecia areata is autoimmune and usually causes round patches or sudden loss; pattern baldness is hormonal and gradual. They need different treatments, so a dermatologist should tell them apart.
Can I get JAK inhibitors without a doctor?
No. JAK inhibitors are prescription immune-modulating drugs with boxed warnings, so they require dermatologist screening, monitoring and supervision — they are not over-the-counter.
Explore more
⚠️ When to see a doctor — don’t self-treat
- Sudden patchy or circular bald spots
- Redness, scaling, pus, pain or itch (possible scarring alopecia — treat urgently)
- Broken hairs or rapid loss
- Loss with body-wide signs (weight loss, fatigue, cycle changes, acne, extra hair)
- Loss right after a new medication
- Any hair loss in a child